TWC
CLDX icon

TD Waterhouse Canada’s Celldex Therapeutics CLDX Stock Holding History

TD Waterhouse Canada’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5
Closed -$217 – 1751
2022
Q4 		$217 Buy
+5
New +$179 ﹤0.01% 1643

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TD Waterhouse Canada's CLDX Position: Q1 2023 in Review

TD Waterhouse Canada sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 5 shares — an estimated $217 sold.

TD Waterhouse Canada first reported a position in CLDX in Q4 2022 and held it in 1 quarter. The position peaked at $217 in Q4 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • TD Waterhouse Canada reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TD Waterhouse Canada sold 5 Celldex Therapeutics shares in Q1 2023, an estimated $217.
  • TD Waterhouse Canada first reported a position in Celldex Therapeutics in Q4 2022 and held it in 1 quarter.
  • TD Waterhouse Canada's Celldex Therapeutics position peaked at $217 in Q4 2022.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on TD Waterhouse Canada's 13F filing for Q1 2023, filed 13 Nov 2023.